Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.3910
-0.0174 (-4.26%)
Mar 31, 2025, 2:29 PM EDT - Market open

Acurx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
8.78.537.3410.782.4
Upgrade
Research & Development
5.46.044.752.032.2
Upgrade
Operating Expenses
14.114.5812.0912.814.6
Upgrade
Operating Income
-14.1-14.58-12.09-12.81-4.6
Upgrade
EBT Excluding Unusual Items
-14.1-14.58-12.09-12.81-4.6
Upgrade
Other Unusual Items
---0.07-
Upgrade
Pretax Income
-14.1-14.58-12.09-12.75-4.6
Upgrade
Net Income
-14.1-14.58-12.09-12.75-4.6
Upgrade
Net Income to Common
-14.1-14.58-12.09-12.75-4.6
Upgrade
Shares Outstanding (Basic)
16131196
Upgrade
Shares Outstanding (Diluted)
16131196
Upgrade
Shares Change (YoY)
27.56%17.15%26.72%37.88%30.29%
Upgrade
EPS (Basic)
-0.87-1.15-1.12-1.49-0.74
Upgrade
EPS (Diluted)
-0.87-1.15-1.12-1.49-0.74
Upgrade
EBIT
-14.1-14.58-12.09-12.81-4.6
Upgrade
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q